Disruptive purification consumables for the pharmaceutical industry
SEPARATIVE is a novel chemical purification and analysis method based on a ground-breaking multicapillary material and the related manufacturing process, both protected by four patents. This brand-new material allows to offer reus...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto Separative
Duración del proyecto: 2 meses
Fecha Inicio: 2018-05-16
Fecha Fin: 2018-07-31
Líder del proyecto
SEPARATIVE
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
SEPARATIVE is a novel chemical purification and analysis method based on a ground-breaking multicapillary material and the related manufacturing process, both protected by four patents. This brand-new material allows to offer reusable low-pressure High-Performance Liquid Chromatography (HPLC) columns. It is the first innovation that achieves chromatographic purification and analysis results without the high pressure and high cost of the state-of-the-art chromatography. SEPARATIVE reduces the cost of current chromatography by a factor of 10-50.
Within the pharmaceutical chromatography market, four types of columns are. Two of these types – flash and preparative – can directly be reached with our first market entrance product range. The flash columns market size is around €240 million and the preparative €110 million. Of those €350 million, we will reach around €240 million with our first business case and then extend the range and the span of the obtainable market. There is a dynamic growth trend with flash columns growing at 10% annually and preparative at 5%.
Being able to use chromatography beyond the experimentation phase would bring several technological advantages to the healthcare industry: Better quality of drugs due to higher purity, lower investments for production plants (savings of 59% for separation), lower manufacturing costs due to better yields (no losses of valuable material in process) and higher security of manufacturing process due to lower volumes of flammable and toxic solvents. This accelerates pharmaceutical innovation and allows citizens to have access to drugs faster.
SEPARATIVE SAS is a start-up hosted at IFPEN (IFP Energies Nouvelles, a major development centre for process industries, renowned worldwide and Nobel Prize for Chemistry in 2005). We are a team of 5 experienced and complementary experts and have access to a great network in chemical engineering as the IFPEN site hosts global leaders such as Total, Solvay, Bluestar and Arkema